Galectin-3, Metabolic Risk, and Incident Heart Failure: The ARIC Study.
diabetes
galectin 3
heart failure
metabolic status
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
pubmed:
13
3
2024
medline:
13
3
2024
entrez:
12
3
2024
Statut:
ppublish
Résumé
It is unclear how metabolic syndrome (MetS) and diabetes affect Gal-3 (galectin 3) levels and the resulting implications for heart failure (HF) risk. We assessed relationships of MetS and diabetes with Gal-3, and their joint associations with incident HF. We included 8445 participants without HF (mean age, 63 years; 59% men; 16% Black race) at ARIC (Atherosclerosis Risk in Communities) study visit 4 (1996-1999). We categorized participants as having MetS only, MetS with diabetes, or neither, and by quartiles of MetS severity MetS and diabetes are associated with elevated Gal-3. The HF risk significantly increased with the combination of greater metabolic risk and higher Gal-3.
Sections du résumé
BACKGROUND
BACKGROUND
It is unclear how metabolic syndrome (MetS) and diabetes affect Gal-3 (galectin 3) levels and the resulting implications for heart failure (HF) risk. We assessed relationships of MetS and diabetes with Gal-3, and their joint associations with incident HF.
METHODS AND RESULTS
RESULTS
We included 8445 participants without HF (mean age, 63 years; 59% men; 16% Black race) at ARIC (Atherosclerosis Risk in Communities) study visit 4 (1996-1999). We categorized participants as having MetS only, MetS with diabetes, or neither, and by quartiles of MetS severity
CONCLUSIONS
CONCLUSIONS
MetS and diabetes are associated with elevated Gal-3. The HF risk significantly increased with the combination of greater metabolic risk and higher Gal-3.
Identifiants
pubmed: 38471823
doi: 10.1161/JAHA.123.031607
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM